

Controlled substance	Drug code	Schedule
Amphetamine ...	1100	II
Lisdexamphetamine.	1205	II
Methylphenidate	1724	II
Phenylacetone ..	8501	II
Tapentadol .....	9780	II

The company plans to bulk manufacture the above-listed controlled substances in bulk for distribution to its customers. No other activities for these drug codes are authorized for this registration.

**Brian S. Besser,**

*Acting Assistant Administrator.*

[FR Doc. 2022-00325 Filed 1-10-22; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-942]

**Bulk Manufacturer of Controlled Substances Application: Johnson Matthey, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Johnson Matthey, Inc., has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 14, 2022. Such persons may also file a written request for a hearing on the application on or before March 14, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on November 2, 2021, Johnson Matthey, Inc., 2003 Nolte Drive West Deptford, New Jersey 08066-1742, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled Substance	Drug Code	Schedule
Gamma Hydroxybutyric Acid ..	2010	I
Marihuana .....	7360	I
Tetrahydrocannabinols .....	7370	I
Noroxymorphone .....	9145	I
Difenoxin .....	9168	I
Amphetamine .....	1100	II
Methamphetamine .....	1105	II
Lisdexamfetamine .....	1205	II
Methylphenidate .....	1724	II
Nabilone .....	7379	II
4-Anilino-N-Phenethyl-4-Piperidine (ANPP).	8333	II
Norfentanyl .....	8366	II
Cocaine .....	9041	II
Codeine .....	9050	II
Dihydrocodeine .....	9120	II
Oxycodone .....	9143	II
Hydromorphone .....	9150	II
Diphenoxylate .....	9170	II
Ecgonine .....	9180	II
Hydrocodone .....	9193	II
Levorphanol .....	9220	II
Meperidine .....	9230	II
Methadone .....	9250	II
Methadone intermediate .....	9254	II
Morphine .....	9300	II
Thebaine .....	9333	II
Opium tincture .....	9630	II
Oxymorphone .....	9652	II
Noroxymorphone .....	9668	II
Alfentanil .....	9737	II
Remifentanil .....	9739	II
Sufentanil .....	9740	II
Tapentadol .....	9780	II
Fentanyl .....	9801	II

The company plans to bulk manufacture the listed controlled substances for the internal use intermediates or for sale to its customers. In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. The company plans to bulk manufacture for either internal usage as intermediates or to sale to customers as Active Pharmaceutical Ingredients (API). No other activities for these drug codes are authorized for this registration.

**Brian S. Besser,**

*Acting Assistant Administrator.*

[FR Doc. 2022-00326 Filed 1-10-22; 8:45 am]

**BILLING CODE P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

[Docket No. DEA-944]

**Importer of Controlled Substances Application: Nexus Pharmaceuticals, Inc.**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Nexus Pharmaceuticals, Inc. has applied to be registered as an

importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 10, 2022. Such persons may also file a written request for a hearing on the application on or before February 10, 2022.

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on October 25, 2021, Nexus Pharmaceuticals, Inc., 10300 128th Avenue, Pleasant Prairie, Wisconsin 53158-7338, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Remifentanil .....	9739	I

The company plans to import the listed controlled substance for research and analytical testing purposes. Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale. No other activity for this drug code is authorized for this registration.

**Brian S. Besser,**

*Acting Assistant Administrator.*

[FR Doc. 2022-00329 Filed 1-10-22; 8:45 am]

**BILLING CODE P**